GlassScriptPhysician profile
Portia Payne
NPI 1578252276
$2,199.89
in general payments reported to CMS, 2019-2025
28 companies · $1,513 in 2025
The $1,513 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $106 · 2024: $581 · 2025: $1,513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,199.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $302.99 | 2024-2025 | |
| Lilly USA, LLC | $203.95 | 2023-2025 | Omvoh, Mounjaro, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $186.47 | 2025 | Entyvio, Eohilia |
| Astrazeneca Pharmaceuticals LP | $147.99 | 2024 | Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $136.89 | 2023-2024 | Trelegy Ellipta, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $133.42 | 2025 | Xifaxan, Plenvu |
| Aimmune Therapeutics, INC. | $131.83 | 2025 | Zenpep, Vowst |
| Genzyme Corporation | $130.05 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $111.29 | 2025 | Dupixent |
| Janssen Biotech, INC. | $96.25 | 2025 | Tremfya |
| Madrigal Pharmaceuticals | $81.17 | 2024-2025 | Rezdiffra, Resmetirom |
| Novo Nordisk INC | $73.69 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Ipsen Biopharmaceuticals, INC | $60.12 | 2025 | Iqirvo |
| Ardelyx, INC. | $58.23 | 2024-2025 | Ibsrela |
| Smith+Nephew, INC. | $45.60 | 2024 | Collagenase Santyl |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $36.83 | 2025 | Voquezna |
| Qol Medical, LLC | $34.63 | 2025 | Sucraid |
| Shield Therapeutics INC | $31.29 | 2023-2024 | Accrufer |
| Celltrion USA INC. | $27.56 | 2025 | Vegzelma |
| Mylan Specialty L.P. | $26.25 | 2024 | Yupelri |
| Mallinckrodt Hospital Products INC. | $21.77 | 2025 | Terlivaz |
| Xeris Pharmaceuticals, INC. | $20.35 | 2024 | Gvoke Hypopen |
| Scilex Pharmaceuticals INC. | $19.93 | 2023 | Ztlido |
| Intercept Pharmaceuticals, INC. | $19.16 | 2025 | |
| Lundbeck LLC | $17.43 | 2024 | Rexulti |
| Ironwood Pharmaceuticals, INC | $16.71 | 2024 | |
| Seqirus USA INC | $14.57 | 2024 | Flucelvax, Fluad |
| Evoke Pharma, INC. | $13.47 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Portia Payne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.